Civica Rx, a not-for profit drug manufacturer founded by seven US health systems and three philanthropic organizations, increased supply security and lowered cost on aggregate for 20 drug products, according to the first empirical evidence of Civica's impact published in the journal NEJM Catalyst.
that have plagued health systems in the US and elsewhere, and now provides more than 75 critical medications at risk for shortages to US health systems."Some problems in health care are so complex that traditional private-sector or governmental interventions alone have not been able to solve the problems," the study says.
The authors estimated that Civica fulfilled its contractually guaranteed volume at 96%, whereas the wholesalers fulfilled their orders at 86%, with the difference being statistically significant . Further, Civica offered an additional product access benefit of 43% above the contractual minimum volume.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why experts predict Bank of England won't lower base rate until summer 2024An increase in interest rates this week could be the last in the current cycle, according to experts
Read more »
Study finds risk factors linked to lower flu vaccine uptake in people with kidney diseaseAmong adults with chronic kidney disease (CKD) enrolled in the Chronic Renal Insufficiency Cohort (CRIC), young age, Black race, and low levels of education and income were associated with lower likelihood of getting an annual flu shot.
Read more »
Earthquakes are unpredictable: Plan ahead to lower the dangerWhen an earthquake struck the center of Morocco earlier this month, killing nearly 3,000 and injuring thousands more, no one was expecting it.
Read more »
Another school sports season: How to lower your child's odds for injuryPlaying sports can offer a lot of benefits for kids, but it's also important to help protect them from injuries.
Read more »
Early convalescent plasma use—helpful in avoiding severe COVID—also may lower long COVID riskFindings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing post-COVID conditions—commonly known as long COVID—if they receive early treatment with plasma from convalescent (recovered) COVID patients that contain antibodies against SARS-CoV-2, the virus that causes COVID-19.
Read more »